Rewriting history
While India took steps to glorious independence, our visionary founder, imagined a nation of ‘accessible and affordable’ healthcare.
Set up in 1943, Biosynth was one of Hyderabad’s premier pharmaceutical companies that rewrote the history books, once and for all.
Today, Biosynth is a company that successfully delivers the latest generation molecules while ensuring the highest quality.
We began by manufacturing Biological products, employed in injections and vaccinations before migrating to lifesaving TB products with PAS sodium, an API that is still our trump card.
We also made rapid inroads into diverse therapy areas and quickly entrenched ourselves as an export house in the late 1900s.
In 2020, a society of technocrats have taken up the mantle to grow Biosynth into an Intermediate and API player of world stature.
Sole mission: Offering products that stand for high quality and advanced chemistry.
Timeline
1943
Forayed in with Biological products
1956
PAS Sodium incorporated into Portfolio
1987
Fused veterinary drugs into Portfolio and maiden export of Ethopabate dispatched on Aug 15th
1990
Audited by Sumitumo, Japan and supplied 100MT of PAS Acid
1993
Audited by Sumitumo, Japan and supplied 100MT of PAS Acid
1994
Marked our entrance into Veterinary drugs with Ethopabate, a highly potent Coccodiostat
1996
Forayed into Gastro therapy with Metoclopramide HCl, a low dose antiemetic
1997
Included Metoclopramide HCl in Portfolio
2000
Integrated Bromomethopabate, Intermediate for Bromopride with Portfolio
2015
Certified by WHO Geneva for PAS Sodium API
2016
‘Export house’ recognition by Govt. of India
2017
Earned Written Confirmation Certificate,CDSCO to export PAS Sodium to EU countries Subsumed Moxifloxacin into Portfolio
2019
Added Amisulpride and Isoniazid to the Portfolio
2020
Introduced Allopurinol to Portfolio
2021
Added key intermediate,4 Hydroxy Carbazole, for Carvedilol API.
Our people. Our panacea.
CEO
K Rama Rao
Mr. K. Rama Rao, CEO, leads Biosynth with his invaluable experience of over 35 years in various aspects of business across diverse industries. In his impressive career span, Rama Rao pioneered the development of Synthesise of Xylazine API (sedative for veterinary use), and other formulations like Nimesulide, Ivermectin injectables for veterinary use.
Rama Rao is a recognized GMP Facilitator by WHO for immunization and vaccines development and Assessor for assessing and implementing Excellence Business Model which includes TQM, by CII Institute of Quality, Bangalore. On a mission to build an excellent organization with improved productivity and profitability, Rama Rao has implemented GMP, QC, QA as well as manufacturing processes and integrated them with the latest management tools such as 5S, TPM, Kaizen, and Lean concepts.
Mr. Mohan Devineni, Executive Director, steers the organization with his vision, leadership, and vast experience of over 40 years in the pharmaceutical sector. Prior to leading Biosynth, he was with Strides Pharma Science Ltd since inception and played several key roles in the growth of the Company. In his last stint he was President/ Director – Strides Pharma Inc., USA, a 100% subsidiary and was also Director on the Board of about ten other subsidiaries in North America.
He joined Biosynth on April 1st, 2021, operates from the USA and is also heading Biosynth, Inc., USA (a 100% subsidiary of Biosynth- India).